[1]谢明珠,朱洪斌,朱 楠,等.CPSF6在晚期非小细胞肺癌中的表达及与预后的关系[J].医学信息,2024,37(04):95-101.[doi:10.3969/j.issn.1006-1959.2024.04.017]
　XIE Ming-zhu,ZHU Hong-bin,ZHU Nan,et al.Expression of CPSF6 in Advanced Non-small Cell Lung Cancer and its Relationship with Prognosis[J].Journal of Medical Information,2024,37(04):95-101.[doi:10.3969/j.issn.1006-1959.2024.04.017]
点击复制

CPSF6在晚期非小细胞肺癌中的表达及与预后的关系()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年04期
页码:
95-101
栏目:
论著
出版日期:
2024-02-15

文章信息/Info

Title:
Expression of CPSF6 in Advanced Non-small Cell Lung Cancer and its Relationship with Prognosis
文章编号:
1006-1959（2024）04-0095-07
作者:
谢明珠; 朱洪斌; 朱 楠; 等
（安徽医科大学附属巢湖医院呼吸与危重症医学科1，病理科2，安徽 巢湖 238000）
Author(s):
XIE Ming-zhu; ZHU Hong-bin; ZHU Nan; et al.
(Department of Respiratory Medicine1,Department of Pathology2,Chaohu Hospital of Anhui Medical University,Hefei 238000,Anhui,China)
关键词:
剪切及多聚腺苷酸化特异因子6; 非小细胞肺癌; 免疫组化
Keywords:
Cleavage and polyadenylation specific factor 6; Non-small cell lung cancer; Immunohistochemistry
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2024.04.017
文献标志码:
A
摘要:
目的 探讨剪切及多聚腺苷酸化特异因子6（CPSF6）在晚期非小细胞肺癌中的表达情况及临床价值。方法 利用TIMER2.0分析CPSF6在各肿瘤组织及癌旁组织中的表达差异，TCGA数据库的可视化平台GEPIA评估CPSF6在泛癌症背景下对总生存期的影响，使用GEPIA2工具比较肺癌不同病理分期（Ⅰ~Ⅳ期）中的CPSF6表达情况，在线检索TCGA数据库中肺腺癌和肺鳞癌的数据集，并进行生存和预后分析。收集2018年1月-2020年3月我院收治的74例晚期非小细胞肺癌患者肿瘤组织以及20例正常肺组织进行CPSF6免疫组化检测，Kaplan-Meier生存分析评估CPSF6表达与晚期非小细胞肺癌患者无进展生存期和总生存期的关系，单因素和多因素分析评估CPSF6对肺癌患者预后的意义。结果 TIMER 2.0、TCGA数据库分析表明非小细胞肺癌患者肿瘤组织中CPSF6 mRNA水平高于癌旁组织（P＜0.05），CPSF6与多种癌症（包括肺腺癌）患者的预后不良有关。CPSF6在晚期非小细胞肺癌组织表达高于正常肺组织，差异有统计学意义（P＜0.05）。CPSF6表达增高与肿瘤大小、淋巴结转移情况及临床分期相关。Kaplan-Meier生存曲线显示，晚期非小细胞肺癌患者CPSF6表达增高，无进展生存期和总生存期降低。单因素及多因素分析显示，CPSF6的表达水平、淋巴结转移和临床分期均可作为晚期非小细胞肺癌患者的独立预后因子（P＜0.05）。结论 CPSF6在晚期非小细胞肺癌组织中表达增高，可能在其预后中发挥重要作用。
Abstract:
Objective To investigate the expression and clinical value of cleavage and polyadenylation specific factor 6 (CPSF6) in advanced non-small cell lung cancer.Methods TIMER2.0 was used to analyze the expression differences of CPSF6 in tumor tissues and adjacent tissues. The visualization platform GEPIA of TCGA database was used to evaluate the effect of CPSF6 on overall survival in the context of pan-cancer. The GEPIA2 tool was used to compare the expression of CPSF6 in different pathological stages (stages Ⅰ-Ⅳ) of lung cancer. The data sets of lung adenocarcinoma and lung squamous cell carcinoma in TCGA database were retrieved online, and survival and prognosis analysis were performed. The tumor tissues of 74 patients with advanced non-small cell lung cancer admitted to our hospital from January 2018 to March 2020 and 20 lung tissues were collected for CPSF6 immunohistochemical detection. Kaplan-Meier survival analysis was used to evaluate the relationship between CPSF6 expression and progression-free survival and overall survival in patients with advanced non-small cell lung cancer. Univariate and multivariate analysis was used to evaluate the prognostic significance of CPSF6 in patients with lung cancer.Results TIMER 2.0 and TCGA database analysis showed that the level of CPSF6 mRNA in tumor tissues of patients with non-small cell lung cancer was higher than that in adjacent tissues (P<0.05). CPSF6 was associated with poor prognosis in patients with various cancers, including lung adenocarcinoma. The expression of CPSF6 in advanced non-small cell lung cancer was higher than that in lung tissue, and the difference was statistically significant (P<0.05). The increased expression of CPSF6 was correlated with tumor size, lymph node metastasis and clinical stage. Kaplan-Meier survival curve showed that CPSF6 expression was increased in patients with advanced non-small cell lung cancer, and progression-free survival and overall survival were decreased. Univariate and multivariate analysis showed that the expression level of CPSF6 protein, lymph node metastasis and clinical stage could be used as independent prognostic factors for patients with advanced non-small cell lung cancer (P<0.05).Conclusion CPSF6 is highly expressed in advanced non-small cell lung cancer tissues and may play an important role in its prognosis.

参考文献/References:

[1]Pan J,Huang Z,Lin H,et al.M7G-Related lncRNAs predict prognosis and regulate the immune microenvironment in lung squamous cell carcinoma[J].BMC Cancer,2022,22(1):1132-1132.[2]Herbst RS,Morgensztern D,Boshoff C.The biology and management of non-small cell lung cancer[J].Nature,2018,553(7689):446-454.[3]黄小明,杜野,林少明,等.呼吸道微生态对晚期非小细胞肺癌患者接受PD-1抑制剂单药治疗疗效影响的探索性研究[J].中国临床药理学与治疗学,2023,28(1):66-74.[4]Duma N,Santana-Davila R,Molina JR.Non-Small Cell Lung Cancer: Epidemiology, Screening,Diagnosis, and Treatment[J].Mayo Clin Proc,2019,94(8):1623-1640.[5]Rotoli D,Santana-Viera L,Ibba ML,et al.Advances in Oligonucleotide Aptamers for NSCLC Targeting[J].International Journal of Molecular Sciences,2020,21(17):6075-6075.[6]Wang BJ,Liu DC,Guo QY,et al.NUDT21 Suppresses Breast Cancer Tumorigenesis Through Regulating CPSF6 Expression[J].Cancer Management and Research,2020,12:3069-3078.[7]陈枞,杜俊娴,蔡承哲,等.CPSF6调控Notch信号通路促进破骨细胞分化及乳腺癌骨转移[J].中国临床医学,2020,27(3):422-427.[8]Tan S,Zhang M,Shi X,et al.CPSF6 links alternative polyadenylation to metabolism adaption in hepatocellular carcinoma progression[J].J Exp Clin Cancer Res,2021,40(1):85. [9]Liu Y,Zou H,Xie Q,et al.Ribonucleic acid-binding protein CPSF6 promotes glycolysis and suppresses apoptosis in hepatocellular carcinoma cells by inhibiting the BTG2 expression[J].Biomed Eng Online,2021,20(1):67.[10]黄进,娄哲琦,朱勇.CPSF6在胶质母细胞瘤进展中的作用及相关调控机制研究[J].中国生物工程杂志,2022,42(9):1-16.[11]Shi X,Ding K,Zhao Q,et al.Suppression of CPSF6 Enhances Apoptosis Through Alternative Polyadenylation-Mediated Shortening of the VHL 3’UTR in Gastric Cancer Cells[J].Front Genet,2021,12:707644. [12]Guo S,Wang G,Zhao Z,et al.Deregulated expression and subcellular localization of CPSF6, a circRNA-binding protein, promote malignant development of esophageal squamous cell carcinoma[J].Chin J Cancer Res,2022,34(1):11-27.[13]张武通,韩健康,张海莲.SCCAg、EGFR及NSE在非小细胞肺癌病情进展、预后预测中的价值[J].分子诊断与治疗杂志,2022,14(9):1511-1514,1518.[14]Zhang Y,Liu L,Qiu Q,et al.Alternative polyadenylation: methods, mechanism, function, and role in cancer[J].Journal of Experimental & Clinical Cancer Research,2021,40(1):51-51.[15]Yuan F,Hankey W,Wagner EJ,et al.Alternative polyadenylation of mRNA and its role in cancer[J].Genes & Diseases,2019,8(1):61-72.[16]Wang L,Hu X,Wang P,et al.Integrative 3’ Untranslated Region-Based Model to Identify Patients with Low Risk of Axillary Lymph Node Metastasis in Operable Triple-Negative Breast Cancer[J].Oncologist,2019,24(1):22-30.[17]Xiang Y,Ye Y,Lou Y,et al.Comprehensive Characterization of Alternative Polyadenylation in Human Cancer[J].J Natl Cancer Inst,2018,110(4):379-389. [18]Zhang Y,Shen L,Shi Q,et al.Comprehensive Analysis of APA Events and Their Association With Tumor Microenvironment in Lung Adenocarcinoma[J].Front Genet,2021,12:645360-645360.

相似文献/References:

[1]田 亮,郭 楠,苗志刚,等.非小细胞肺癌中ZEB1和FoxO3a表达及意义[J].医学信息,2018,31(03):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
　TIAN Liang,GUO Nan,MIAO Zhi-gang,et al.Expression and Significance of ZEB1 and FoxO3a in Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(04):16.[doi:10.3969/j.issn.1006-1959.2018.03.006]
[2]陶 洪,孙国平.非小细胞肺癌根治术后复发及进展影响因素的回顾性分析[J].医学信息,2018,31(12):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
　TAO Hong,SUN Guo-ping.Retrospective Analysis of Factors Influencing Recurrence and Progression after Radical Resection of Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(04):61.[doi:10.3969/j.issn.1006-1959.2018.12.019]
[3]李春磊,裴艳志,邹志田,等.非小细胞肺癌组织中趋化因子受体CCR7的 表达及其临床意义[J].医学信息,2018,31(17):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
　LI Chun-lei,PEI Yan-zhi,ZOU Zhi-tian,et al.Expression of Chemokine Receptor CCR7 in Non-small Cell Lung Cancer and its Clinical Significance[J].Journal of Medical Information,2018,31(04):14.[doi:10.3969/j.issn.1006-1959.2018.17.004]
[4]杨 莉.TP方案联合回生口服液治疗中晚期非小细胞肺癌的疗效观察[J].医学信息,2018,31(17):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
　YANG Li.Therapeutic Effect of TP Regimen Combined with Huisheng Oral Liquid in the Treatment of Advanced Non-small Cell Lung Carcinoma[J].Journal of Medical Information,2018,31(04):17.[doi:10.3969/j.issn.1006-1959.2018.17.005]
[5]吴森林,高 斌.中性粒细胞/淋巴细胞比值与介入治疗中晚期非小细胞肺癌患者预后的相关性[J].医学信息,2019,32(03):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
　WU Sen-lin,GAO Bin.Correlation between Neutrophil/Lymphocyte Ratio and Prognosis in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(04):82.[doi:10.3969/j.issn.1006-1959.2019.03.025]
[6]田春琴,赵新汉,蒋冬梅,等.二线用药EGFR-TKIs治疗非选择型NSCLC疗效的Meta分析[J].医学信息,2018,31(20):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
　TIAN Chun-qin,ZHAO Xin-han,JIANG Dong-mei,et al.Meta-analysis of the Efficacy of Second-line EGFR-TKIs in the Treatment of Nonselective NSCLC[J].Journal of Medical Information,2018,31(04):49.[doi:10.3969/j.issn.1006-1959.2018.20.015]
[7]徐闻霞,陆红艳,黄 斌.胸腔镜肺叶切除和肺段切除治疗ⅠA期非小细胞肺癌的疗效比较[J].医学信息,2018,31(21):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
　XU Wen-xia,LU Hong-yan,HUANG Bin.Comparison of Thoracoscopic Lobectomy and Segmentectomy for ⅠA Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(04):100.[doi:10.3969/j.issn.1006-1959.2018.21.027]
[8]付红星,冯小剑,彭文苗,等.康艾注射液联合化疗治疗晚期非小细胞肺癌的临床研究[J].医学信息,2018,31(24):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
　FU Hong-xing,FENG Xiao-jian,PENG Wen-miao,et al.Clinical Study of Kang'ai Injection Combined with Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(04):115.[doi:10.3969/j.issn.1006-1959.2018.24.033]
[9]阳 芳,黄 斌,覃超群,等.血清KL-6水平与安罗替尼治疗的非小细胞肺癌预后的关系[J].医学信息,2022,35(12):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
　YANG Fang,HUANG Bin,QIN Chao-qun,et al.Relationship Between Serum KL-6 Level and Prognosis of Non-small Cell Lung Cancer Treated with Anlotinib[J].Journal of Medical Information,2022,35(04):104.[doi:10.3969/j.issn.1006-1959.2022.12.025]
[10]贾殿军,王利军,程险峰,等.可手术的非小细胞肺癌患者外周静脉血cfDNA总浓度及长片段DNA浓度的临床价值研究[J].医学信息,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]
　JIA Dian-jun,WANG Li-jun,CHENG Xian-feng,et al.Clinical Value of Total cfDNA Concentration and Long Fragment DNA Concentration in Peripheral Venous Blood of Patients with Operative Non-small Cell Lung Cancer[J].Journal of Medical Information,2019,32(04):91.[doi:10.3969/j.issn.1006-1959.2019.04.030]

更新日期/Last Update: 1900-01-01